Physician profile
Sharon Levy
NPI 1316396807
$4,401.40
in general payments reported to CMS, 2019-2025
25 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $935 · 2023: $723 · 2024: $1,059 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $919.25 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $622.88 | 2021-2025 | |
| Kaleo, INC. | $384.07 | 2021-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $376.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $339.42 | 2021-2025 | Tezspire, Airsupra |
| Grifols USA, LLC | $256.97 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $215.10 | 2023-2025 | Cinryze, Eohilia, Hyqvia |
| Csl Behring | $195.75 | 2023-2025 | Hizentra, Andembry |
| Abbvie INC. | $186.89 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $142.96 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $114.26 | 2024-2025 | Ruconest |
| Pfizer INC. | $104.70 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $84.67 | 2025 | |
| Octapharma USA, INC. | $73.67 | 2024-2025 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Ars Pharmaceuticals Operations, INC. | $62.79 | 2025 | Neffy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $55.60 | 2023-2024 | Ayvakit |
| Amgen INC. | $55.22 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $44.14 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Ionis Pharmaceuticals, INC. | $31.41 | 2025 | Dawnzera |
| Hospira, INC. | $29.93 | 2022 | |
| Lilly USA, LLC | $23.50 | 2025 | Ebglyss |
| Incyte Corporation | $22.57 | 2024 | Opzelura |
| Optinose US, INC. | $22.32 | 2023 | |
| Genentech USA, INC. | $19.34 | 2024 | Xolair |
| Arcutis Biotherapeutics, INC. | $17.68 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.